Pola-R-CHP与R-CHOP一线治疗DLBCL的真实世界疗效与复发特征比较
这项回顾性多中心队列研究在倾向评分匹配队列中比较了Pola-R-CHP与R-CHOP一线治疗初治DLBCL的疗效。Pola-R-CHP组1年PFS优于R-CHOP组(86.7% vs 73.5%,p=0.027),但1年OS相似。Pola-R-CHP组结内复发率显著更低,但结外及中枢神经系统复发仍是挑战。
要点
- Pola-R-CHP组1年PFS优于R-CHOP组,但1年OS无显著差异。
- Pola-R-CHP组结内复发率显著低于R-CHOP组。
- CNS-IPI可分层Pola-R-CHP组中枢神经系统复发累积发生率。
核心结论
- Pola-R-CHP一线治疗DLBCL的临床疗效优于R-CHOP,但早期结外复发和中枢神经系统复发仍是治疗挑战。
研究设计与样本
- 回顾性多中心队列研究,从1096例初治DLBCL患者中经倾向评分匹配形成370例队列,其中Pola-R-CHP组匹配185例、全队列356例。
主要发现
- Pola-R-CHP组1年PFS为86.7%,R-CHOP组为73.5%(p=0.027)。
- Pola-R-CHP组1年OS为92.8%,R-CHOP组为89.6%(p=0.24)。
- Pola-R-CHP组1年结内复发发生率为2.1%,R-CHOP组为10.9%(p=0.013)。
- Pola-R-CHP组1年结外复发发生率为3.8%,R-CHOP组为5.2%(p=0.57)。
- Pola-R-CHP组中CNS-IPI低、中、高危组中枢神经系统复发累积发生率分别为0%、2.1%、4.5%(p=0.023)。
临床怎么用
- Pola-R-CHP可作为初治DLBCL的一线治疗选择,但需关注早期结外及中枢神经系统复发风险。
- CNS-IPI可用于Pola-R-CHP治疗患者的中枢神经系统复发风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this retrospective, multicentre cohort study, we compared the real-world efficacy of polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) versus the conventional rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in 370 patients in the propensity score matching cohort from 1096 patients with previously untreated diffuse large B-cell lymphoma (DLBCL) (pola; n = 185 in the matched and 356 in the full cohort). The analysis focused on clinical efficacy, the prognostic performance of established risk models and the relapse profiles with the chemotherapies. The Pola-R-CHP group showed superior 1-year progression-free survival (PFS) compared to the R-CHOP group (86.7% vs. 73.5%, p = 0.027); however, the 1-year overall survival (OS) was similar (92.8% vs. 89.6%, p = 0.24). Within the Pola-R-CHP group, the Central Nervous System International Prognostic Index (CNS-IPI) effectively stratified the cumulative incidence of CNS relapse of 0%, 2.1% and 4.5% in the low, intermediate and high-risk groups respectively (p = 0.023). Additionally, the 1-year incidence of nodal relapse was significantly lower in the Pola-R-CHP group than in the R-CHOP group (2.1% vs. 10.9%, p = 0.013), whereas the incidence of extra-nodal relapse remained similar (3.8% vs. 5.2%, p = 0.57). These findings underscore the clinical efficacy of Pola-R-CHP over R-CHOP in first-line DLBCL treatment. However, early extra-nodal relapse and CNS relapse remained a therapeutic challenge.
引用
- Terao T, Yoshida I, Kobayashi H, et al. Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study. Br J Haematol. 2025. PMID: 41451861. doi:10.1111/bjh.70280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。